Hepatocyte growth factor - Nxera Pharma
Latest Information Update: 02 Apr 2024
At a glance
- Originator Osaka University School of Medicine
- Developer Mitsubishi Tanabe Pharma Corporation; Nxera Pharma; Sumitomo Pharma
- Class Antifibrotics; Growth factors; Neuropsychotherapeutics
- Mechanism of Action Angiogenesis inducing agents; Hepatocyte growth factor stimulants; Intercellular signalling peptide and protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Arterial occlusive disorders; Thromboangiitis obliterans; Vascular disorders